Immunic, Inc.

Stocks

IMUX

US4525EP2001

Market Closed - Nasdaq 21:00:00 25/09/2026 BST			5-day change	1st Jan Change
9.345 ^USD	+0.27%		-12.01%	+75.10%

09-11	Immunic, Inc. Announces Resignation of Duane Nash as Member of the Board of Directors	CI
09-09	Immunic, Inc. - Special Call

Transcript : Immunic, Inc. - Special Call

Published on 09/09/2026 at 10:10 pm BST - Modified on 09/11/2026 at 02:38 pm BST

S&P Capital IQ

Presenter Speech
Jessica Breu (Executives)

All right. Good morning to everyone on our webinar today, and welcome to Immunic's Virtual R&D Day focusing on our relapsing MS development program with

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Immunic, Inc.

09-11	Immunic, Inc. Announces Resignation of Duane Nash as Member of the Board of Directors	CI
09-09	Immunic, Inc. - Special Call
09-01	Roth Capital Partners Adjusts Price Target on Immunic to $29 From $19, Maintains Buy Rating	MT
09-01	Immunic, Inc. Announces Appointment of Chitrang Davé to Chief Data and Digital Officer, Effective September 1, 2026	CI
08-17	Wedbush Initiates Immunic at Outperform With $45 Price Target	MT
08-11	Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-10	Immunic, Inc. Announces Appointment of Elena Ridloff to Board of Directors, Effective August 6, 2026	CI
07-06	Immunic, Inc. Announces Board and Committee Changes	CI
06-29	Immunic, Inc.(NasdaqCM:IMUX) added to Russell Microcap Value Benchmark Index	CI
06-28	Immunic, Inc.(NasdaqCM:IMUX) added to Russell 3000E Value Benchmark	CI
05-28	Immunic Presents Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium At Cmsc Annual Meeting	CI
05-27	Immunic, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026	CI
05-27	Immunic Names Erik Lundgren Chief Executive	DJ
05-27	Immunic Appoints Former Genentech Executive Erik Lundgren as CEO	MT
05-22	B. Riley Adjusts Price Target on Immunic to $27 From $40, Maintains Buy Rating	MT

Chart Immunic, Inc.

Duration

Period

IMUX: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data

Ratings

More Ratings

EPS Estimates

Revisions to estimates